PSC
ARCT icon

Piper Sandler & Co’s Arcturus Therapeutics ARCT Stock Holding History

Piper Sandler & Co’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1,663
Closed -$73K – 10
2016
Q1 		$73K Hold
1,663
– – 0.16% 9
2015
Q4 		$73K Buy
+1,663
New +$74.9K 0.19% 18

Other funds holding ARCT

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Piper Sandler & Co's ARCT Position: Q2 2016 in Review

Piper Sandler & Co sold out of Arcturus Therapeutics (ARCT) in Q2 2016, closing a stake of 1,663 shares — an estimated $73K sold.

Piper Sandler & Co first reported a position in ARCT in Q4 2015 and held it in 2 quarters. The position peaked at $73K in Q1 2016. 45 funds tracked by Wall St. Rank hold ARCT as of Q2 2016.

  • Piper Sandler & Co reported no remaining Arcturus Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Piper Sandler & Co sold 1,663 Arcturus Therapeutics shares in Q2 2016, an estimated $73K.
  • Piper Sandler & Co first reported a position in Arcturus Therapeutics in Q4 2015 and held it in 2 quarters.
  • Piper Sandler & Co's Arcturus Therapeutics position peaked at $73K in Q1 2016.
  • 45 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2016.

Based on Piper Sandler & Co's 13F filing for Q2 2016, filed 15 Aug 2016.